Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Iadademstat in Combination With Paclitaxel in Relapsed or Refractory Small Cell Lung Cancer and Extrapulmonary High Grade Neuroendocrine Carcinomas

NCT05420636 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT05420636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05420636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Iadademstat in Combination With Paclitaxel in Relapsed or Refractory Small Cell Lung Cancer and Extrapulmonary High Grade Neuroendocrine Carcinomas
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
December 21, 2022
Completion date
July 23, 2025
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma, small-cell lung cancer